Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Public ClinicalTrials.gov record NCT01742988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Study identification
- NCT ID
- NCT01742988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Curis, Inc.
- Industry
- Enrollment
- 106 participants
Conditions and interventions
Conditions
- Double-expressor Lymphoma (DEL)
- Double-hit Lymphoma (DHL)
- High-grade B-cell Lymphoma (HGBL)
- Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Refractory Lymphoma
- Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)
- Relapsed Lymphoma
- Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Relapsed and/or Refractory Lymphoma
- Triple-hit Lymphoma (THL)
Interventions
- Rituximab Drug
- fimepinostat Drug
- venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012
- Primary completion
- Oct 8, 2020
- Completion
- Oct 8, 2020
- Last update posted
- May 5, 2021
2012 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Stephenson Cancer Center, University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01742988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01742988 live on ClinicalTrials.gov.